4-氯-3-(羟基((3-羟基-2,3-二甲基丁-2-基)氧基)硼烷基)苯甲酸甲酯 | 710350-72-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-3-(羟基((3-羟基-2,3-二甲基丁-2-基)氧基)硼烷基)苯甲酸甲酯
• 英文名称: methyl 4-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
• CAS: 710350-72-4
• 化学式: C₁₄H₁₈BClO₄
• 分子量: 296.559
• InChiKey: WDDNUAMATJHVNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.43
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-5-methoxycarbonylphenylboronic acid pinacol ester
Synonyms: Methyl 4-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-5-methoxycarbonylphenylboronic acid pinacol ester
CAS number: 710350-72-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C14H18BClO4
Molecular weight: 296.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-3-(羟基((3-羟基-2,3-二甲基丁-2-基)氧基)硼烷基)苯甲酸甲酯 在 四(三苯基膦)钯 、 N,N-二甲基甲酰胺 lithium hydroxide 、 草酰氯 、 水 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 38.5h， 生成 4-chloro-3-(3,5-dichloro-pyridin-2-yl)-N-(2-hydroxy-phenyl)-N-methyl-benzamide
  参考文献：
  名称：

  WO2008/124610

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氯-3-碘苯甲酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 硫酸 、 potassium acetate 作用下， 以 二甲基亚砜 为溶剂， 反应 22.0h， 生成 4-氯-3-(羟基((3-羟基-2,3-二甲基丁-2-基)氧基)硼烷基)苯甲酸甲酯
  参考文献：
  名称：

  [EN] HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF
  [FR] MODULATEURS HÉTÉROCYCLIQUES DE LA SYNTHÈSE DES LIPIDES ET COMBINAISONS EN CONTENANT

  摘要：

  提供了杂环调节剂脂质合成以及其药用盐；包括这些化合物的药物组合物；以及通过给予这些化合物和其他治疗剂的组合来治疗脂肪酸合酶途径失调症状的方法。

  公开号：

  WO2015095767A1

文献信息

• [EN] HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE LA SYNTHÈSE DES LIPIDES
  申请人：3 V BIOSCIENCES INC

  公开号：WO2014008197A1

  公开（公告）日：2014-01-09

  Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

  提供了异环调节脂质合成的调节剂及其药用盐；包括这些化合物的药物组合物；以及通过给予这些化合物来治疗由于脂肪酸合酶途径失调而表现出的疾病的方法。
• Structure‐Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5‐ <i>b</i> ]Pyridin‐2‐one‐Based p38 MAP Kinase Inhibitors: Part 2
  作者：Akira Kaieda、Masashi Takahashi、Hiromi Fukuda、Rei Okamoto、Shinji Morimoto、Masayuki Gotoh、Takahiro Miyazaki、Yuri Hori、Satoko Unno、Tomohiro Kawamoto、Toshimasa Tanaka、Sachiko Itono、Terufumi Takagi、Hiroshi Sugimoto、Kengo Okada、Weston Lane、Bi‐Ching Sang、Kumar Saikatendu、Shinichiro Matsunaga、Seiji Miwatashi

  DOI：10.1002/cmdc.201900373

  日期：2019.12.17

  yl-1H-pyrazol-3-yl)benzamide (25) exhibited potent p38 inhibition, superior suppression of TNF-α production in hWB cells, and also significant in vivo efficacy in a rat model of collagen-induced arthritis (CIA). In this paper, we report the discovery of potent, selective, and orally bioavailable imidazo[4,5-b]pyridin-2-one-based p38 MAP kinase inhibitors.

  我们使用基于结构的设计策略，从铅化合物3-（butan-2-yl）-6-（2,4-difluoroanilino）-1， 3-二氢-2H-咪唑并[4，5-b]吡啶-2-酮（1）。为了增强1在人全血（hWB）细胞测定中对肿瘤坏死因子-α（TNF-α）产生的抑制活性，我们设计并合成了其中咪唑并[4,5-b] pyridin-2的杂化化合物。 -一个核心与对甲基苯甲酰胺片段成功连接。在所评估的化合物中，3-（3-叔丁基-2-氧代-2,3-二氢-1H-咪唑并[4,5-b]吡啶-6-基）-4-甲基-N-（1-甲基-1H-吡唑-3-基）苯甲酰胺（25）在hWB细胞中显示出有效的p38抑制作用，TNF-α产生的优异抑制作用，并且在胶原诱导的关节炎（CIA）大鼠模型中也具有显着的体内功效。
• Cyanomethyl derivatives as cysteine protease inhibitors
  申请人：Graupe Michael

  公开号：US20060122184A1

  公开（公告）日：2006-06-08

  The present invention is directed to cyanomethyl derivatives that are inhibitors of cysteine protease, in particular, cathepsin B, K, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及氰甲基衍生物，其是半胱氨酸蛋白酶的抑制剂，特别是对于B、K、F和S型的卡特普辛，因此可用于治疗由这些蛋白酶介导的疾病。本发明还涉及包含这些化合物的制药组合物和其制备过程。
• Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
  申请人：Neurocrine Biosciences, Inc.

  公开号：US08084614B2

  公开（公告）日：2011-12-27

  GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  本发明公开了GnRH受体拮抗剂，其在男性和女性的多种与性激素相关的疾病治疗中具有用途。本发明的化合物具有以下结构，其中R1a，R1b，R1c，R1d，R2，R2a和A的定义如本文中所述，包括立体异构体，酯类，溶剂化物和其药学上可接受的盐。本发明还公开了含有本发明化合物与药学上可接受的载体的组合物，以及与其相关的用于在需要时抗agonadotropin-releasing hormone的方法。
• GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
  申请人：Beaton Graham

  公开号：US20100152207A1

  公开（公告）日：2010-06-17

  GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R 1a , R 1b , R 1c , R 1d , R 2 , R 2a , and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  本发明揭示了GnRH受体拮抗剂，其在治疗男性和女性的多种性激素相关疾病中具有实用性。本发明的化合物具有以下结构，其中R1a，R1b，R1c，R1d，R2，R2a和A的定义如本文所述，包括立体异构体，酯类，溶剂合物和其药学上可接受的盐。本发明还揭示了含有本发明化合物与药学上可接受的载体的组合物，以及与其相关的方法，用于在需要的受试者中对抗促性腺激素释放激素。